

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

02 Jul 2026

### Comparison of efficacy and safety of topical 5% potassium hydroxide solution and topical 0.1% retinoid lotion in the treatment of plane wart

#### Protocol summary

##### Summary

Purpose: The comparison of efficacy and safety of topical potassium hydroxide 5% and topical retinoid 0.1% in the treatment of plane wart Design of the study: randomized The population of the study: patients with at least three lesions of plane wart Sample size: 72 patients, 36 patients in each group Interventions: application of topical 5% hydroxide potassium solution in one group and topical 0.1% retinoid lotion in another group Time of intervention: 23-10-2009 until 06-08-2010 Outcome: both drugs have similar efficacy in the treatment of plane wart, adverse drug reaction was higher in KOH group than retinoid group.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201201038516N2**

Registration date: **2012-03-10, 1390/12/20**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2012-03-10, 1390/12/20

##### Registrant information

##### Name

Mahroo Tajalli

##### Name of organization / entity

Ahvaz Jundishapur University of Medical Science

##### Country

Iran (Islamic Republic of)

##### Phone

+98 14 1322 0101

##### Email address

tajalli.m@ajums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Ahvaz jundishapur University of Medical Science

##### Expected recruitment start date

2009-10-23, 1388/08/01

##### Expected recruitment end date

2010-08-06, 1389/05/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparison of efficacy and safety of topical 5% potassium hydroxide solution and topical 0.1% retinoid lotion in the treatment of plane wart

##### Public title

Comparison of efficacy and safety of topical 5% potassium hydroxide solution and topical 0.1% retinoid lotion in the treatment of plane wart

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criterion: presence of at least three lesion  
Exclusion criteria: 1-Pregnancy 2-Lactation 3-Patients that have received treatment in the recent four weeks 4-Secondary infection 5-Involvement of the genital area

##### Age

No age limit

##### Gender

Both

##### Phase

N/A

##### Groups that have been masked

No information

##### Sample size

Target sample size: 72

### Randomization (investigator's opinion)

Randomized

### Randomization description

### Blinding (investigator's opinion)

Not blinded

### Blinding description

### Placebo

Not used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ahvaz Jundishapurl university of medical science

##### Street address

Ahvaz Jundishapurl university of medical science-  
Golestan Blvd-Ahvaz-Khuzestan-Iran

##### City

Ahvaz

##### Postal code

#### Approval date

2009-10-17, 1388/07/25

#### Ethics committee reference number

ETH-030

## Health conditions studied

### 1

#### Description of health condition studied

plane wart

#### ICD-10 code

B00-B09

#### ICD-10 code description

Viral infections characterized by skin and mucous  
membrane lesions

## Primary outcomes

### 1

#### Description

Improvement

#### Timepoint

2 weeks, 4 weeks, 6 weeks after initiation of the  
treatment and 2 weeks after the end of the treatment

#### Method of measurement

Based on the count of lesions

## Secondary outcomes

### 1

#### Description

Adverse drug reaction

#### Timepoint

2 weeks, 4 weeks, 6 weeks after the initiation of the  
treatment and 2 weeks after the end of the treatment

#### Method of measurement

Based on occurrence of various adverse reaction

## Intervention groups

### 1

#### Description

Topical 5% potassium hydroxide solution was applied on  
the lesions using cotton swap by patients or their  
parents, and then patients were evaluated regarding  
efficacy and safety of the drugs 2, 4, 6 weeks after the  
initiation of the treatment and 2 weeks after the end of  
the treatment.

#### Category

Treatment - Drugs

### 2

#### Description

In the other group topical 0.1 % retinoid lotion was  
applied on the wart lesions by the patient or their  
parents and the patients were evaluated regarding the  
efficacy and safety 2, 4, 6 weeks after the initiation of  
the treatment and 2 weeks after the end of treatment.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Department of dermatology-Imam Khomeini hospital-  
Ahvaz

##### Full name of responsible person

Dr Mahroo Tajalli

##### Street address

Imam Khomeini hospital- Azadegan avenue-Ahvaz-  
Khuzestan-Iran

##### City

Ahvaz

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

The institute of research and technology of Ahvaz  
jundishapur University of Medical Science

##### Full name of responsible person

Dr Mostafa Fegghi

##### Street address

Ahvaz Jundishapur University of Medical Science-  
Golestan Blvd- Ahvaz- Iran

**City**

Ahvaz

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

The institute of research and technology of Ahvaz  
jundishapur University of Medical Science

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Ahvaz Jundishapur University of Medical Science

**Full name of responsible person**

Dr Mahroo Tajalli

**Position**

resident of dermatology

**Other areas of specialty/work**

**Street address**

Imam Khomeini hospital- Ahvaz

**City**

Ahvaz

**Postal code**

**Phone**

+98 61 1222 2114

**Fax**

+98 61 1292 1837

**Email**

mahru.tajalli@yahoo.comtajalli.m@ajums.ac.ir

**Web page address**

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Ahvaz Jundishapur University of Medical Science

**Full name of responsible person**

Dr Reza Yaghoobi

**Position**

Full professor in the field of dermatology at Ahvaz  
University of Medical Science

**Other areas of specialty/work**

**Street address**

Imam Khomeini hospital-Ahvaz

**City**

Ahvaz

**Postal code**

**Phone**

+98 61 1222 2114

**Fax**

**Email**

yaghoobi\_rz@yahoo.com

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Ahvaz Jundishapur University of Medical Science

**Full name of responsible person**

Dr Mahroo Tajalli

**Position**

Resident of dermatology

**Other areas of specialty/work**

**Street address**

Imam Khomeini hospital-Ahvaz

**City**

Ahvaz

**Postal code**

**Phone**

+98 61 1222 2114

**Fax**

+98 61 1292 1837

**Email**

mahru.tajalli@yahoo.comtajalli.m@ajums.ac.ir

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*